Preoperative micro-axial support and planned RVAD were associated with improved 1 year survival after durable LVAD surgery; whether this reflects a causal relationship where the preconditioning of the right ventricle improves postoperative outcomes cannot be determined from this retrospective design.
Abstract
Patients requiring a right ventricular assist device (RVAD) after durable left ventricular assist device (LVAD) surgery have historically worse outcomes than those with isolated LVADs. Preoperative mechanical circulatory support (MCS) with venoarterial extracorporeal membrane oxygenation (ECMO) or micro-axial pumps complicates right heart assessment by altering loading conditions. We examined 1 year outcomes of patients receiving temporary RVADs at the time of durable LVAD. From February 2017 to August 2025, 102 patients were reviewed. Right ventricular assist device decannulation, ventilator liberation, and intensive care unit (ICU) discharge were assessed using Fine-Gray subdistribution analysis with death as a competing risk; 1 year survival was evaluated by Kaplan-Meier analysis. Analysis included 59 planned, 28 unplanned, and 15 delayed RVADs (45 percutaneous, 57 surgical). One year survival was 64.0 ± 6.5% for planned, 50.2 ± 10.3% for unplanned, and 50.3 ± 13.6% for delayed RVAD. Percutaneous and surgical RVAD survival were 60.1 ± 7.5% and 55.1 ± 7.1%. Preoperative MCS was independently associated with improved survival (hazard ratio [HR]: 0.36, confidence interval [CI]: 0.17-0.83), with micro-axial pump showing the strongest association. Preoperative micro-axial support and planned RVAD were associated with improved 1 year survival after durable LVAD surgery; whether this reflects a causal relationship where the preconditioning of the right ventricle improves postoperative outcomes cannot be determined from this retrospective design.
Biventricular assist device (BiVAD) use has decreased in the pediatric population, partly driven by concerns that survival may be inferior compared with that achieved with isolated left ventricular assist devices (LVAD). We aimed to address whether the timing of right ventricular assist device (RVAD) impacts these outc...
Shannon Oliver, M. Bleiweis, M. O'Connor et al.· ASAIO journal (1992)· 0 citations
T-VAD was the predominant temporary RV support strategy at the authors' institution and was feasible, with favorable observed survival in this descriptive single-center experience, and was associated with significantly greater perioperative resource utilization.
Matthan Tharakan, Luis M. Quiroz, Steven C. Stroud et al.· JHLT open· 0 citations
The Impella 5.5 is a surgically implanted micro-axial left ventricular assist device (LVAD) increasingly utilized for mechanical circulatory support (MCS) in cardiogenic shock. While typically used for acute support up to FDA-approved 14 days, reports of prolonged utilization remain limited. We present the case of a 69...
J. Shimamura, A. Levine, Stephen Pan et al.· Artificial Organs· 1 citation
These findings suggest LVAD explant identifies a higher-risk transplant phenotype shaped by surgical burden, device-associated physiologic effects, and allocation-era transplant timing, rather than by intrinsic device-related risk alone.
Walter Navid, Chen-Chia Wang, A. Ahmad et al.· Annals of Thoracic Surgery· 0 citations
It is suggested that ECMO can stabilize the condition of these high-risk patients, and bridging to LVAD can relieve the pressure on the donor heart and improve prognosis.
Y. Shen, Y. Dong, Q.-S. Wu et al.· Zhonghua yi xue za zhi· 0 citations
RVFW strain and coupling indexes derived from catheterization and echocardiographic RV strain imaging can aid with the need for an RVAD and RHF risk stratification following LVAD implantation.
Michael Schäfer, S. S. Bakhtiyar, T. Hanff et al.· JACC: Advances· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.